Current and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy
Open Access
- 7 June 2010
- journal article
- review article
- Published by Wiley in Brain Pathology
- Vol. 20 (4) , 845-856
Abstract
Mutations in the ABCD1 gene cause the clinical spectrum of the neurometabolic disorder X‐linked adrenoleukodystrophy/adrenomyeloneuropathy (X‐ALD/AMN). Currently, the most efficient therapeutic opportunity for patients with the cerebral form of X‐ALD is hematopoietic stem cell transplantation and possibly gene therapy of autologous hematopoietic stem cells. Both treatments, however, are only accessible to a subset of X‐ALD patients, mainly because of the lack of markers that can predict the onset of cerebral demyelination. Moreover, for female or male X‐ALD patients with AMN, currently only unsatisfying therapeutic opportunities are available. Thus, this review focuses on current and urgently needed future pharmacological therapies. The treatment of adrenal and gonadal insufficiency is well established, whereas applications of immunomodulatory and immunosuppressive drugs have failed to prevent progression of cerebral neuroinflammation. The use of Lorenzo's oil and the inefficacy of lovastatin to normalize very‐long‐chain fatty acids in clinical trials as well as currently experimental and therefore possible future therapeutic strategies are reviewed. The latter include pharmacological gene therapy mediated by targeted upregulation of ABCD2, the closest homolog of ABCD1, antioxidative drug treatment, small molecule histone deacetylase inhibitors such as butyrates and valproic acid, and other neuroprotective attempts.Keywords
This publication has 112 references indexed in Scilit:
- Pathomechanisms Underlying X‐Adrenoleukodystrophy: A Three‐Hit HypothesisBrain Pathology, 2010
- HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damageNature Neuroscience, 2009
- Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cellsNature Reviews Drug Discovery, 2009
- Quantitative magnetization transfer characteristics of the human cervical spinal cord in vivo: Application to AdrenomyeloneuropathyMagnetic Resonance in Medicine, 2008
- Oxidative Stress in Parkinson's DiseaseAnnals of the New York Academy of Sciences, 2008
- The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline levelFree Radical Biology and Medicine, 2008
- Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatinJournal of Neurochemistry, 2008
- The relationship between dose of vitamin E and suppression of oxidative stress in humansFree Radical Biology and Medicine, 2007
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Pharmacological strategies for muscular dystrophyNature Reviews Drug Discovery, 2003